Reviewer's report

Title: Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma

Version: 1 Date: 6 December 2009

Reviewer: Tianshu Liu

Reviewer's report:

1. It is a retrospective study, we cannot learn from the text about the representativeness of the patients selected in this study?
2. Regular and split-dose FMP were given according to the patients status, rather than randomly, selection bias existed obviously, which will affect the final results;
3. Few patients received more than one cycle of FMP, so how about its applicability in the clinic?
4. Toxicities reported more in split dose group, is that related with the quite late stage or poor performance of the patients ?
5. How about the other treatments in this group of patients, like TACE, RFA?

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.